Beta-blocker treatment group

ApprovedRecruiting

0 watching 0 views this week🔥 Hot

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Idiopathic Ventricular Fibrillation

Conditions

Idiopathic Ventricular Fibrillation, Cardiac Arrest, Out-Of-Hospital

Trial Timeline

May 1, 2018 → Dec 31, 2035

NCT ID

NCT07405229

About Beta-blocker treatment group

Beta-blocker treatment group is a approved stage product being developed by Novo Nordisk for Idiopathic Ventricular Fibrillation. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07405229. Target conditions include Idiopathic Ventricular Fibrillation, Cardiac Arrest, Out-Of-Hospital.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07405229	Approved	Recruiting	May 1, 2018	Dec 31, 2035	Idiopathic Ventricular Fibrillation

Competing Products

20 competing products in Idiopathic Ventricular Fibrillation

See all competitors

Product	Company	Stage	Hype Score
KPL-716 + Placebo	Kiniksa Pharmaceuticals	Phase 2	47
Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03) + Placebo	Rein Therapeutics	Phase 1	25
LTI-03 + Placebo	Rein Therapeutics	Phase 1	25
LTI-03 + Placebo	Rein Therapeutics	Phase 2	44
Tirzepatide + Tirzepatide Placebo	Eli Lilly	Approved	85
MRA(Tocilizumab)	Chugai Pharmaceutical	Phase 3	77
MRA(Tocilizumab) + placebo	Chugai Pharmaceutical	Phase 3	77
MRA(Tocilizumab)	Chugai Pharmaceutical	Phase 3	77
MRA(Tocilizumab)	Chugai Pharmaceutical	Phase 3	77
Zimura + Eylea	Astellas Pharma	Phase 2	52
Avacincaptad Pegol	Astellas Pharma	Phase 2	52
Rituximab + cyclosporine	Sun Pharmaceutical	Phase 3	77
E5501	Eisai	Phase 1	33
E5501 + Drug: E5501	Eisai	Phase 1	33
E5501 40 mg 2 x 20-mg tablets, orally, fasted + E5501 40 mg 2 x 20-mg tablets, orally, with food + E5501 40mg 2 x 20-mg tablets, orally, fasted + E5501 40 mg 2 x 20-mg tablets, orally, with food	Eisai	Phase 1	33
Eltrombopag + Avatrombopag + Standard of care	Eisai	Phase 3	77
Placebo + Avatrombopag tablets	Eisai	Phase 2	52
Perampanel	Eisai	Pre-clinical	23
Blinded (placebo) + Open Label (Avatrombopag tablets) + Blinded (Avatrombopoag tablets)	Eisai	Phase 2	52
Istradefylline 20 mg or 40 mg	Kyowa Kirin	Phase 3	77

Other Products from Novo Nordisk

Liraglutide 3.0mg + Placebo Oral Tablet + Phentermine 15 MGApproved

Liraglutide + SalineApproved

Hydrocortisone + PlaceboApproved

biphasic insulin aspart + insulin aspartApproved

Semaglutide, 1.34 mg/mL + Empagliflozin 25 MGApproved